LIVE - GCOS 2021 - Virtual Day Two

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published over 180 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks including the chapter on cardiotoxicity of tyrosine kinase inhibitors in the latest edition of the ESC Textbook of Cardiology. He is a deputy editor of the European Heart Journal, an associate editor of the European Journal of Heart Failure, international advisor to the journal JACC Cardio-Oncology and his H-index is 44. Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society, recently appointed a board member of International Cardio-Oncology Society (ICOS - 2021), chair-elect European Society of Cardiology (ESC) Council of Cardio-Oncology (2020-2022) and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M). Alex is a co-chair of the first ESC Cardio-Oncology Guideline which will be published in 2022. Alex completed a full 4 year term on the board of the Heart Failure Association of the ESC (2016-2020), and he initiated and was the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.

Ana Barac, MD PhD is an Associate Professor of Medicine and Oncology at Georgetown University and the director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. She specializes in advanced cardiovascular imaging and cardiovascular care of oncology patients. Dr Barac serves an Associate Editor of JACC Cardio-Oncology and a co-director of the ACC Live Course on Advancing CV Care of Oncology patient. She was the founding Chair of the American College of Cardiology (ACC) Cardio-Oncology Council.

Anecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing Cardio-Oncology Program at The University of Texas MD Anderson Cancer Center. Dr. Fadol is a nursing pioneer in the evolving field of cardio-oncology. Her extensive and unique expertise in cardio-oncology have been recognized nationally and internationally. She has written numerous book chapters, published in peer-reviewed journals, and is the editor of the “Cardiac Complications of Cancer Therapy”, the first clinical reference book for nurses that examines the complexity of cardiac problems in conjunction with a cancer diagnosis. Her program of research included the validation of the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument, which was subsequently translated to Chinese and Spanish. She is on the leadership council for the Cardio-Oncology section of the American College of Cardiology. Dr. Fadol is a fellow of the American Academy of Nurse Practitioners, American Academy of Nursing, and was recently awarded as Honorary Fellow of 2021 by the Hong Kong Academy of Nursing.

Dr. Arnold is a native New Yorker and studied General and Interventional Cardiology at the Cleveland Clinic Foundation in Cleveland, Ohio, USA. As a cancer survivor herself, she is passionate about Cardio-Oncology and presently is an Associate Professor of Medicine at Florida State University, the Founding Director of the Cardio-Oncology program and Transitional Clinic for childhood cancer survivors at Lee Health in Florida, a Board of Director member and Chair of the Education Committee for ICOS, and the past chair of the Advocacy working group for the Cardio-Oncology section of the American College of Cardiology. She is interested in disparities in healthcare especially as it relates to Cardio-Oncology.

Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.

Dra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa de São Paulo School of Medicine, São Paulo, Brazil. She is also chair of the cardio-oncology department of Rede D’Or São Luiz health network and researcher/faculty at BCRI (Brazilian Clinical Research Institute). Her clinical background includes MD and Master in Health Sciences at the University of Minas Gerais, Brazil. Currently, she is finishing the Ph.D. program at the Federal University of São Paulo, Brazil. She is an active member of scientific organizations serving now as Vice President of the cardio-oncology chapter of the Brazilian Society of Cardiology, Director of the Brazilian Society of Thrombosis and Hemostasis, and Member of the Council of Cardio-Oncology of the Interamerican Society of Cardiology. In 2019 she was certified to be a fellow of the European Society of Cardiology. She is currently developing consensus documents in cardio-oncology and the definition of core educational topics to provide structured training in cardio-oncology.

Dr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London and at University College London Hospital (UCLH). He is the first cardiologist in the UK to be appointed specifically in cardio-oncology and helped establish Cardio-Oncology services at both these hospitals which are now amongst the biggest services worldwide. Arjun leads the cardio-oncology service at UCLH. Arjun is also actively involved in developing cardio-oncology curricula and guidelines and changing practice through the British Society of Echocardiography, British Cardio-Oncology Society and International Cardio-Oncology Society and UK Specialist Advisory Committee (SAC). He was joint first author of the first British cardio-oncology guidelines published earlier this year. He runs the UK’s only national Cardio-Oncology Study Day and help organise the only pan-European Cardio-oncology Symposium. Outside of the interesting world of cardiology’s newest subspecialty Arjun is involved in cardiac MRI (CMR) and cardio-oncology echocardiography and has several national and international leadership and management positions at the British Cardiovascular Society, the Royal Society of Medicine, the British Cardio-Oncology Society and the International Cardio-Oncology Society. He is the co-host of the ICOS podcast and has recently been appointed to the ACC Cardio-Oncology Leadership Council. You can find him on Twitter @arjunkg.

Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK. His clinical and research is focused on amyloidosis with a particular interest in cardiac amyloidosis. He leads the AL program for UK. His is the director of the Jack O’Neil Amyloidosis laboratory which is focused on amyloid typing and genomics. He leads UK’s first dedicated amyloidosis treatment clinic at University College London Hospitals and is leading development of a UK National Amyloidosis Treatment Network. He leads AL amyloidosis treatment and research in the UK. His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on several national and international clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.

Dr. Bénédicte Lefebvre is an Assistant Professor of Clinical Medicine at the University of Pennsylvania. Dr. Lefebvre earned her medical degree from McGill University, Montreal, Canada where she also completed her training in internal medicine and general adult cardiology. She then completed a two-year fellowship in advanced cardiac imaging at the University of Pennsylvania specializing in echocardiography, structural echocardiography and cardiac magnetic resonance. Afterwards, she underwent a cardio-oncology fellowship at the University of Pennsylvania. Dr. Lefebvre’s research focuses on the cardiovascular effects of CAR T cells and the use of cardiac imaging and biomarkers to detect cardiotoxicity.

Charles Porter MD established the Cardio-oncology program for the University of Kansas Cancer at the University of Kansas Medical Center in 2007. He was designated as the inaugural American Vice-President of IC-OS in 2009. He has overseen the growth of the KUMC cardio-oncology program and continues to expand its collaboration with a broad array of oncologists in patient care and research. Research includes studies in BMT outcomes, 5FU cardiotoxicity and breast cancer treatment cardiotoxicity. He is associate editor for Cardiooncology, an editorial consultant for JACC Cardiooncology, and is a member of the IC-OS Science and Research Committee. He has multiple publications and presentations in the field.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular Physiopathology in 2009. She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan. Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment.

Dr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Scientist. Dr. Thavendiranathan’s Clinical work involves cardiac MRI, CT, and echocardiography and Cardio-oncology. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He holds a Canada Research Chair in Cardio-oncology.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Lauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology & Biomedical Imaging at Yale School of Medicine in New Haven, CT. She is the Director of the Yale Smilow Cancer Center Cardio-Oncology Program and the Cardiology Director of Cardiac MR/CT for Yale New Haven Hospital. She is also the Program Director for the newly established Yale Cardio-Oncology Advanced Fellowship Program. Dr. Baldassarre is a member of the American College of Cardiology Cardio-Oncology Section Leadership Council and is the Chair of the International Cardio-Oncology Society Imaging Work Group. She is the Chair of the Society for Cardiovascular Magnetic Resonance Cardio-Oncology Special Interest Group and is a member of the Society of Cardiovascular Computed Tomography Cardio-Oncology Writing Group. Her clinical and research interests include the use of advanced multimodality cardiac imaging for the detection, management, and prevention of cardiotoxicity from cancer therapeutics.

Dr Scott Adams is an Assistant Scientist (Toronto General Hospital Research Institute, University Health Network [UHN]) and the Exercise Lead (Ted Rogers Cardiotoxicity Prevention Program, UHN). He is the Director of the ‘Research in Exercise & Cardiorespiratory Health in Oncology’ laboratory (UHN) and a member of the Adolescent and Young Adult Oncology Program (Princess Margaret Cancer Centre) and the Cardiovascular Prevention and Rehabilitation Program (Toronto Rehab Institute). He completed his PhD at the University of Alberta and two post-doctoral fellowships at Memorial Sloan Kettering Cancer Center and the University of Toronto. His research adopts precision medicine and knowledge translation approaches to (1) phenotype cancer patients and survivors using complementary cardiovascular profiling tools (e.g. cardiopulmonary exercise testing, vascular imaging, autonomic function assessments) to augment cardiovascular risk screening and stratification, (2) develop targeted exercise-based multi-modal therapies that target the discrete mechanisms of risk and injury within these phenotype-defined groups, and (3) facilitate the translation of this and related research into practice.

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.

Dr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan Health, Indianapolis, Indiana. He graduated with a dual degree MD and PhD from the Medical University of South Carolina followed by Internal Medicine training at Duke University Medical Center. He then completed Cardiology fellowship at the University of California, San Francisco followed by a dedicated additional year in echocardiography serving as the Chief Fellow. He is the governor-elect for the Indiana Chapter of the American College of Cardiology. Under his leadership, the Franciscan CardioOncology team was awarded an Associate of Community Cancer Centers National Innovator Award in 2020 for “Nurse Navigation as a Model for Developing an CardioOncology Program.” Dr. Rao was also the first author on a recent State of the Art Review published in Journal of American College of Cardiology June 2021 issue titled “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents.” He also serves as the Chair of the ICOS Center of Excellence Committee and is an active member of the ICOS Education Committee.